Download Free The Economic And Social Dynamics Of Biotechnology Book in PDF and EPUB Free Download. You can read online The Economic And Social Dynamics Of Biotechnology and write the review.

`Biotechnology' - the integrated use of biochemistry, microbiology, and chemical engineering for the technological application of the capabilities of microbes and cultured tissue cells - is quickly becoming pervasive and challenging, rapidly developing both new techniques and industries. The Economic and Social Dynamics of Biotechnology - a joint project between Statistics Canada, the Program of Research on Innovation, Management and Economy (PRIME) at the University of Ottawa, and CIRANO at the University of Quebec in Montreal - brings together economic, social, and statistical views on the dynamics of this set of emerging technologies. It examines the costs as well as the benefits - the challenges as well as the choices - of the rapidly expanding science-based world of biodiversity, biopharmaceuticals, and bioinformatics, and it provides suggestions for future work and research. This project fits into an ongoing research program at Statistics Canada to develop meaningful indicators for science, technology, and innovation in a technology-intensive economy. This book tells the story of the inner workings of innovation systems, technological systems, and competence blocs in the production, use, and diffusion of knowledge.
"Contains some essays of two international conferences both organized by Fondazione Edison ;... "Districts, pillars, network facilities" [and] "New science, new industry-the challenges for new Europe".
Between 1973 and 2016, the ways to manipulate DNA to endow new characteristics in an organism (that is, biotechnology) have advanced, enabling the development of products that were not previously possible. What will the likely future products of biotechnology be over the next 5â€"10 years? What scientific capabilities, tools, and/or expertise may be needed by the regulatory agencies to ensure they make efficient and sound evaluations of the likely future products of biotechnology? Preparing for Future Products of Biotechnology analyzes the future landscape of biotechnology products and seeks to inform forthcoming policy making. This report identifies potential new risks and frameworks for risk assessment and areas in which the risks or lack of risks relating to the products of biotechnology are well understood.
A challenge of our generation is the creation of an efficient system providing sustainable food and fuel from the land whilst also preserving biodiversity and ecosystems. We must feed a human population that is expected to grow to more than nine billion by mid-century. Agricultural biotechnology is one tool that holds potential promise to alleviate hunger and poverty. However, there are complex and interrelated scientific, social, political and ethical questions regarding the widespread use of biotechnology in the food supply. This edited volume discusses diverse perspectives on sustainable food production systems in terms of challenges, opportunities, success stories, barriers and risks associated with agricultural and food biotechnology. The effects of biotechnology on the environment, ethical and moral issues, potential changes to government policies and economics, and social implications are summarised. This book will interest students, professionals and researchers from the areas of bioengineering, agriculture and ecosystem science to economics and political science.
'All would agree that with more than 3, 000 new firms formed in Europe, Japan and the United States focused on biotechnology, and with elegant strides forward in our understanding of genetics, the genome, proteomics and other related fields, a true intellectual, social and industrial revolution is in the making. Maureen McKelvey et al provide fascinating data on firm formation, case studies of emerging business models and cross-regional and national comparisons. The work is a useful beginning in our understanding of an emerging phenomenon.' - James M. Utterback, Massachusetts Institute of Technology, US This book offers a novel insight into the economic dynamics of modern biotechnology, using examples from Europe to reflect global trends. The authors apply theoretical insight to a fundamental enigma of the modern learning society, namely, how and why the development of knowledge and ideas interact with market processes and the formation of industries and firms.
Focusing on the period between the 1970s and the present, Life as Surplus is a pointed and important study of the relationship between politics, economics, science, and cultural values in the United States today. Melinda Cooper demonstrates that the history of biotechnology cannot be understood without taking into account the simultaneous rise of neoliberalism as a political force and an economic policy. From the development of recombinant DNA technology in the 1970s to the second Bush administration's policies on stem cell research, Cooper connects the utopian polemic of free-market capitalism with growing internal contradictions of the commercialized life sciences. The biotech revolution relocated economic production at the genetic, microbial, and cellular level. Taking as her point of departure the assumption that life has been drawn into the circuits of value creation, Cooper underscores the relations between scientific, economic, political, and social practices. In penetrating analyses of Reagan-era science policy, the militarization of the life sciences, HIV politics, pharmaceutical imperialism, tissue engineering, stem cell science, and the pro-life movement, the author examines the speculative impulses that have animated the growth of the bioeconomy. At the very core of the new post-industrial economy is the transformation of biological life into surplus value. Life as Surplus offers a clear assessment of both the transformative, therapeutic dimensions of the contemporary life sciences and the violence, obligation, and debt servitude crystallizing around the emerging bioeconomy.
Providing the first overview of Asia’s emerging biosciences landscape, this timely and important collection brings together ethnographic case studies on biotech endeavors such as genetically modified foods in China, clinical trials in India, blood collection in Singapore and China, and stem-cell research in Singapore, South Korea, and Taiwan. While biotech policies and projects vary by country, the contributors identify a significant trend toward state entrepreneurialism in biotechnology, and they highlight the ways that political thinking and ethical reasoning are converging around the biosciences. As ascendant nations in a region of postcolonial emergence, with an “uncanny surplus” in population and pandemics, Asian countries treat their populations as sources of opportunity and risk. Biotech enterprises are allied to efforts to overcome past humiliations and restore national identity and political ambition, and they are legitimized as solutions to national anxieties about food supplies, diseases, epidemics, and unknown biological crises in the future. Biotechnological responses to perceived risks stir deep feelings about shared fate, and they crystallize new ethical configurations, often re-inscribing traditional beliefs about ethnicity, nation, and race. As many of the essays in this collection illustrate, state involvement in biotech initiatives is driving the emergence of “biosovereignty,” an increasing pressure for state control over biological resources, commercial health products, corporate behavior, and genetic based-identities. Asian Biotech offers much-needed analysis of the interplay among biotechnologies, economic growth, biosecurity, and ethical practices in Asia. Contributors Vincanne Adams Nancy N. Chen Stefan Ecks Kathleen Erwin Phuoc V. Le Jennifer Liu Aihwa Ong Margaret Sleeboom-Faulkner Kaushik Sunder Rajan Wen-Ching Sung Charis Thompson Ara Wilson
This book explores how the biotechnology and pharmaceutical sector is affected by innovation, growth and public policy.
How the asset—anything that can be controlled, traded, and capitalized as a revenue stream—has become the primary basis of technoscientific capitalism. In this book, scholars from a range of disciplines argue that the asset—meaning anything that can be controlled, traded, and capitalized as a revenue stream—has become the primary basis of technoscientific capitalism. An asset can be an object or an experience, a sum of money or a life form, a patent or a bodily function. A process of assetization prevails, imposing investment and return as the key rationale, and overtaking commodification and its speculative logic. Although assets can be bought and sold, the point is to get a durable economic rent from them rather than make a killing on the market. Assetization examines how assets are constructed and how a variety of things can be turned into assets, analyzing the interests, activities, skills, organizations, and relations entangled in this process. The contributors consider the assetization of knowledge, including patents, personal data, and biomedical innovation; of infrastructure, including railways and energy; of nature, including mineral deposits, agricultural seeds, and “natural capital”; and of publics, including such public goods as higher education and “monetizable social ills.” Taken together, the chapters show the usefulness of assetization as an analytical tool and as an element in the critique of capitalism. Contributors Thomas Beauvisage, Kean Birch, Veit Braun, Natalia Buier, Béatrice Cointe, Paul Robert Gilbert, Hyo Yoon Kang, Les Levidow, Kevin Mellet, Sveta Milyaeva, Fabian Muniesa, Alain Nadaï, Daniel Neyland, Victor Roy, James W. Williams
The Business of Healthcare Innovation is the first wide-ranging analysis of business trends in the manufacturing segment of the health care industry. In this leading edge volume, Professor Burns focuses on the key role of the 'producers' as the main source of innovation in health systems. Written by professors of the Wharton School and industry executives, this book provides a detailed overview of the pharmaceutical, biotechnology, genomics/proteomics, medical device and information technology sectors. It analyses the market structures of these sectors as well as the business models and corporate strategies of firms operating within them. Most importantly, the book describes the growing convergence between these sectors and the need for executives in one sector to increasingly draw upon trends in the others. It will be essential reading for students and researchers in the field of health management, and of great interest to strategy scholars, industry practitioners and management consultants.